JACQUELINE MURILLO: Open Payments
NPI 1962179275 · MIDDLEBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,457 in 41 payments from 10 companies in 2025. Trend: 2023 $1,343 · 2024 $1,864 · 2025 $1,457
Food & beverage: $1,457
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $628 |
| Vanda Pharmaceuticals Inc. | 7 | $260 |
| Supernus Pharmaceuticals, Inc. | 6 | $241 |
| Gilead Sciences, Inc. | 1 | $122 |
| Neurocrine BioSciences, Inc. | 3 | $86 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $28 |
| Indivior Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
Products named: VRAYLAR, FANAPT, Qelbree, Yeztugo, INGREZZA, REXULTI, Auvelity, SUBLOCADE.
Industry payments across CT — which companies pay providers there.
